zoledronic acid




Zuellig Pharma
Concise Prescribing Info
Zoledronic acid
Treatment & prevention of postmenopausal & glucocorticoid-induced osteoporosis. Osteoporosis in men. Paget's disease. Prevention of clinical fractures after a hip fracture.
Dosage/Direction for Use
Treatment & prevention of postmenopausal & glucocorticoid-induced osteoporosis, osteoporosis in men, prevention of clinical fractures after a hip fracture 5 mg IV infusion once a year. Paget's disease 5 mg single IV infusion. Administer over at least 15 min.
Hypersensitivity to bisphosphonates. Hypocalcemia. Severe renal impairment w/ CrCl <35 mL/min. Pregnancy & lactation.
Special Precautions
Ensure appropriate hydration prior to administration. Adequate Ca & vit D intake prior to therapy in patients w/ preexisting hypocalcemia, & for 10 days following therapy in patients w/ Paget's disease of bone. Monitor for other mineral metabolism disorders. Avoid invasive dental procedures for those who develop osteonecrosis of the jaw.
Adverse Reactions
Headache, dizziness, nausea, vomiting, diarrhea, myalgia, arthralgia, bone & back pain, pain in extremities, fever, flu-like symptoms, chills, fatigue, asthenia, malaise, decreased appetite, tremor, lethargy, conjunctivitis, eye pain, iritis, abdominal pain, upper abdominal pain, constipation, night sweats, musculoskeletal pain, muscle spasms, musculoskeletal chest pain, jaw & neck pain.
Drug Interactions
May cause dehydration w/ nephrotoxic drugs eg, aminoglycosides, or diuretics.
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BA08 - zoledronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Aclasta inj 5 mg/100 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in